AbbVie's (ABBV) Atrasentan Receives Orphan Drug Designation

September 30, 2016 8:17 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

AbbVie (NYSE: ABBV) Atrasentan for treatment of pediatric nephrotic syndrome was granted an FDA Orphan Drug Designation.

Generic Name: Atrasentan
Trade Name: N/A
Date Designated: 09/29/2016
Orphan Designation: Treatment of pediatric nephrotic syndrome
Orphan Designation Status: Designated
FDA Orphan Approval Status:Not FDA Approved for Orphan Indication
Marketing Approval Date: N/A
Approved Labeled Indication:
Exclusivity End Date: N/A
AbbVie Inc.
Regulatory Affairs
1 North Waukegan Road
North Chicago, Illinois 60044

The sponsor address listed is the last reported by the sponsor to OOPD.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment